Quanterix launches LucentAD biomarker test to aid early Diagnosis of Alzheimer’s Disease
Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, yesterday announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD). The LucentAD test, which will be available to healthcare providers as an aid in […]
